Lawrence Einhorn, MD
Lawrence Einhorn, MD, has been on the IU School of Medicine Department of Medicine faculty since 1973. His field of expertise includes clinical trials and supportive care, with focus in the areas of lung and testicular cancers. Dr. Einhorn has also been involved in the clinical development of new drug therapies. Studies chaired by Dr. Einhorn at IU School of Medicine in the area of testicular cancer led to the FDA approval of cisplatin, etoposide and ifosfamide. In addition, his groups conducted the pivotal studies that led to the approval of both gemcitabine and pemetrexed in non-small cell lung cancer.
A major current area of focus for Dr. Einhorn is supportive care and survivorship, especially as it applies to patients who are cured with platinum-based chemotherapy for testicular cancer. He has been a long-standing member of the Multi-National Association for Supportive Care in Cancer (MASCC).
Dr. Einhorn's clinical interests include solid tumor oncology, specifically within the fields of genitourinary and lung cancers. His legacy will forever be linked with revolutionizing testicular cancer treatment. Prior to Dr. Einhorn's research in the area of platinum combination chemotherapy in patients with metastatic testicular cancer, the survival rate of the disease was approximately 10 percent. Now, due to Dr. Einhorn's monumental findings, the current survival rate for metastatic testicular cancer is at 80 percent.
Dr. Einhorn rose to even greater prominence when he used his novel treatment paradigm to treat Lance Armstrong, cancer advocate and seven-time winner of the Tour de France. With Dr. Einhorn's treatment, Armstrong survived stage 3 testicular cancer that initially presented with abdominal, brain and lung metastases. Like Armstrong, Einhorn remains dedicated to raising cancer awareness. He was appointe the first Lance Armstrong Foundation professor of oncology in 2006.
Indiana Cancer Pavilion, Suite 473 535 Barnhill Dr
Indianapolis, IN 46202-5289
Titles & Appointments
- Livestrong Foundation Professor of Oncology
- Professor of Medicine
Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ Cell Tumors: A Hoosier Cancer Research Network Study GU14-206.
Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
Multidisciplinary Clinic Approach Improves Overall Survival Outcomes of Patients with Metastatic Germ Cell Tumors.
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.
Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
Randomized Pilot Trial of a Telephone Symptom Management Intervention for Symptomatic Lung Cancer Patients and Their Family Caregivers.
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.
Outcomes of postchemotherapy retroperitoneal lymph node dissection following high-dose chemotherapy with stem cell transplantation.
The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Pitfalls in management of patients with germ cell tumors and slight elevation of serum a-fetoprotein.
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.
Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients.
Metastatic Malignant Transformation of Teratoma to Primitive Neuroectodermal Tumor (PNET): Results With PNET-based Chemotherapy.
Support service use and interest in support services among distressed family caregivers of lung cancer patients.
The "growing teratoma syndrome" in primary mediastinal nonseminomatous germ cell tumors: criteria based on current practice.
Signet ring cell carcinoma of the testis: clinicopathologic and molecular evidence for germ cell tumor origin--a case report.
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors.
Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma.
Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology.
Survival after resection for metastatic testicular nonseminomatous germ cell cancer to the lung or mediastinum.
Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection?
Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.
Perceptions of masculinity and self-image in adolescent and young adult testicular cancer survivors: implications for romantic and sexual relationships.
Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements.
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery.
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.
Gefitinib plus celecoxib in chemotherapy-naļve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer.
Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience.
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.
National Academy of Science
Desc: Richard and Hinda Rosenthal Award for Cancer Research
Org: American Cancer Society
Desc: Medal of Honor Winner
Org: National Cancer Institute
Desc: Outstanding Investigator Grant
Org: M.D. Anderson
Desc: Gottlieb Award
Org: American Society of Clinical Oncology
Desc: Karnofsky Award
Org: General Motors Foundation
Desc: Kettering Prize for Cancer Research
Org: American Association of Cancer Research
Desc: Joseph Burchenal Award
Org: National Cancer Center Directors Meeting
Desc: First Annual Award for Lifetime Achievement in Cancer Control